Clinical trial update: National Cancer Institute of Canada

The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Pritchard, Kathy, Whelan, Tim
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064133/
https://www.ncbi.nlm.nih.gov/pubmed/15743510
http://dx.doi.org/10.1186/bcr979
_version_ 1782123305191342080
author Pritchard, Kathy
Whelan, Tim
author_facet Pritchard, Kathy
Whelan, Tim
author_sort Pritchard, Kathy
collection PubMed
description The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therapy. The Group has also fostered, together with the NCIC CTG Investigational New Drug (IND) Program, a series of phase II and phase I/II studies which will be carried through if possible, into the phase III setting.
format Text
id pubmed-1064133
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-10641332005-03-11 Clinical trial update: National Cancer Institute of Canada Pritchard, Kathy Whelan, Tim Breast Cancer Res Commentary The Breast Cancer Site Group (BCSG) of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) has conducted a wide variety of clinical trials focussing on large phase III trials of adjuvant chemotherapy, adjuvant hormonal therapy, and optimal delivery of adjuvant radiation therapy. The Group has also fostered, together with the NCIC CTG Investigational New Drug (IND) Program, a series of phase II and phase I/II studies which will be carried through if possible, into the phase III setting. BioMed Central 2005 2005-01-12 /pmc/articles/PMC1064133/ /pubmed/15743510 http://dx.doi.org/10.1186/bcr979 Text en Copyright © 2005 BioMed Central Ltd
spellingShingle Commentary
Pritchard, Kathy
Whelan, Tim
Clinical trial update: National Cancer Institute of Canada
title Clinical trial update: National Cancer Institute of Canada
title_full Clinical trial update: National Cancer Institute of Canada
title_fullStr Clinical trial update: National Cancer Institute of Canada
title_full_unstemmed Clinical trial update: National Cancer Institute of Canada
title_short Clinical trial update: National Cancer Institute of Canada
title_sort clinical trial update: national cancer institute of canada
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064133/
https://www.ncbi.nlm.nih.gov/pubmed/15743510
http://dx.doi.org/10.1186/bcr979
work_keys_str_mv AT pritchardkathy clinicaltrialupdatenationalcancerinstituteofcanada
AT whelantim clinicaltrialupdatenationalcancerinstituteofcanada

Ejemplares similares